Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to ...
The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback